Company intelligence / Profile preview

Pharmos Corporation

Iselin, New Jersey, United Statespharmoscorp.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Dextofisopam showed statistically significant efficacy in IBS patients in Phase IIa. NanoEmulsion cream for topical NSAID delivery was also studied in osteoarthritis. The company’s synthetic cannabinoid platform demonstrated promising preclinical results for neuropathic pain and other indications. No recent clinical data available post-late 2000s.

Therapeutic areas: GastroenterologyImmunologyNeurologyRheumatology
Modalities: Small moleculesTopical drug delivery systems (NanoEmulsion cream)Synthetic cannabinoids/CB2-selective agonists
Industry: Biotech

Drug pipeline

3 assets

dextofisopam

2 more assets in the full pipeline.

Request access →

Partnerships

VenrockNew Enterprise Associates

Beyond the preview

Go deeper on Pharmos Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharmos Corporation.

Explore the full profile